Business · 16/05/2025
Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same
The National Center for Advancing Translational Sciences is contemplating an Exclusive Patent License grant to Neurala Bio, Inc. to practice inventions related to c-Abl Tyrosine Kinase Inhibitory Compound Embodiments.
Original source language: Federal Register — Health and Human ServicesOpen original release →